Dr. Hani Abdullah Al-Hadrami is a consultant and associate professor of molecular diagnostics and medical biotechnology at King Abdul Aziz University.
He recently received a US patent and trademark for inventing a COVID-19 early detection and diagnostic method that uses low-cost technology and provides results in record time, without using polymerase chain reaction analysis.
He received a bachelor’s degree in medical technology in 2004 from King Abdul Aziz University. Following that, he began his higher education journey at the University of Aberdeen, UK, where he obtained a master’s degree in biotechnology and microbiology with distinction in 2007.
About four years later, he obtained a Ph.D. in medical biotechnology from the College of Life Sciences and Medicine at the same university.
Al-Hadrami has been a visiting assistant professor at Harvard Medical School and Harvard-MIT Health Sciences and Technology.
His research contributions at Harvard Medical School focused on the development of aptamer-based microfluidic electrochemical biosensors for continuous monitoring of heart-on-a-chip platforms.
Al-Hadrami is a research fellow at the Center of Excellence in Genomic Medicine Research and the Special Infectious Agents Unit at King Abdul Aziz University, where he also leads the research group on medical nanobiotechnology.
Al-Hadrami, who has featured in international peer-reviewed journals, is experienced in the development, characterization and optimization of several bioluminescence-based biosensors for mutagenicity, carcinogenicity and toxicity assessments.
His expertise involves the medical application of biosensors, microfluidics, lab-on-a-chip platforms, biosensors for pathogenic virus and bacteria detection, and nanoparticles as a delivery system to provide tumor-suppressor proteins and cancer treatment drugs.
